Table 1.

moDC markers 1 day after stimulation. The geometric mean expression relative to no treatment (“none”’) was expressed as the fold change for CD11c, CD40, CD86 and CCR7 gated on live cells and % CCR7 + high moDCs gated on CD11c + /CD40 + . H,M,L: concentrations of virosome-included 3D-PHAD 0.95 µg/ml (H) 0.19 µg/ml (M) 0.038 µg/ml (L), and QS-21 H: 0.95 µg/ml, M, 0.38 µg/ml, L: 0.076 µg/ml

Vaccine			Cells		Relative geometric mean expression of marker (fold change)
	QS21	3D PHAD	% in live gate	% CCR7 high	CD11c	CD40	CD86	CCR-7
None			71.9	1.08	1.00	1.00	1.00	1.00
Peptide alone			75.6	0.95	0.99	0.97	0.88	1.01
Amplivant-SLP			70.0	1.52	0.83	0.99	1.39	1.16
Empty virosomes			77.2	1.16	1.37	1.17	1.24	1.40
Amplivant-SLP virosomes			51.2	3.49	1.37	1.27	1.70	1.64
Amplivant-SLP virosomes	High		48.3	2.91	1.17	1.23	1.80	1.58
Amplivant-SLP virosomes	High	High	57.3	3.63	1.31	1.39	2.06	2.42
Amplivant-SLP virosomes	High	Medium	51.9	3.76	1.45	1.48	2.13	2.01
Amplivant-SLP virosomes	High	Low	48.8	3.29	0.83	0.94	1.80	2.41
Amplivant-SLP virosomes	Medium		50.5	2.01	1.43	1.35	1.97	1.61
Amplivant-SLP virosomes	Medium	High	53.6	1.82	0.82	0.96	1.58	2.25
Amplivant-SLP virosomes	Medium	Medium	53.5	2.49	1.04	1.36	2.18	1.08
Amplivant-SLP virosomes	Medium	Low	61.5	1.85	1.19	1.23	1.82	1.85
Amplivant-SLP virosomes	Low		50.2	3.18	1.28	1.15	1.80	1.63
Amplivant-SLP virosomes	Low	High	60.1	2.47	1.28	1.40	2.08	2.48
Amplivant-SLP virosomes	Low	Medium	60.7	2.18	0.67	0.86	1.68	1.74
Amplivant-SLP virosomes	Low	Low	55.0	2.86	1.10	1.27	2.12	1.17
Amplivant-SLP virosomes		High	43.1	3.41	1.29	1.29	1.80	1.64
Amplivant-SLP virosomes		Medium	48.9	3.55	1.41	1.40	1.97	2.31
Amplivant-SLP virosomes		Low	56.9	4.09	1.34	1.37	1.96	2.73